Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants

Inclusion criteria

• Healthy participants ≥6 months and ≤45 years of age at enrolment
• Participants/Parents/Legally Authorized Representative(LAR) willing to give written informed consent/assent to participate in the trial
• Participants/Parents/LAR willing to follow the study procedures of the study and available for the entire duration of the study
• Participants who are healthy as determined by medical history, with no clinically significant abnormalities in clinical examination and laboratory tests
• Female participants must have a negative serum (at Screening) and negative urinary (at Day 1) pregnancy test and agree to use 2 methods of contraception from dosing until 90 days after vaccination.

Exclusion criteria

• Participants/Parents/LAR unwilling to give his/her consent/assent to participate in the trial
• Participants concomitantly enrolled or scheduled to be enrolled in another trial
• Children and infants with a congenital abnormality
• Known history of immune function disorders including immunodeficiency disease, or chronic use of systemic steroids, cytotoxic or other immunosuppressive drugs
• Pregnant, lactating women or women of childbearing age not using a reliable method of contraception
• History of uncontrolled coagulopathy or blood disorders
• Any abnormality or chronic disease which in the opinion of the investigator might be detrimental for the safety of the participant and interfere with the assessment of the trial objectives
• History of alcohol or substance abuse